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ABSTRACT
Introduction Worldwide, 2 million patients aged 18–50 
years suffer a stroke each year, and this number is 
increasing. Knowledge about global distribution of risk 
factors and aetiologies, and information about prognosis 
and optimal secondary prevention in young stroke 
patients are limited. This limits evidence- based treatment 
and hampers the provision of appropriate information 
regarding the causes of stroke, risk factors and prognosis 
of young stroke patients.
Methods and analysis The Global Outcome Assessment 
Life- long after stroke in young adults (GOAL) initiative aims 
to perform a global individual patient data meta- analysis 
with existing data from young stroke cohorts worldwide. 
All patients aged 18–50 years with ischaemic stroke or 
intracerebral haemorrhage will be included. Outcomes will 
be the distribution of stroke aetiology and (vascular) risk 
factors, functional outcome after stroke, risk of recurrent 
vascular events and death and finally the use of secondary 
prevention. Subgroup analyses will be made based on age, 
gender, aetiology, ethnicity and climate of residence.
Ethics and dissemination Ethical approval for the GOAL 
study has already been obtained from the Medical Review 
Ethics Committee region Arnhem- Nijmegen. Additionally 
and when necessary, approval will also be obtained 
from national or local institutional review boards in the 
participating centres. When needed, a standardised data 
transfer agreement will be provided for participating 
centres. We plan dissemination of our results in peer- 
reviewed international scientific journals and through 
conference presentations. We expect that the results of 
this unique study will lead to better understanding of 
Strengths and limitations of this study
 ► By combining existing individual data sets, the 
Global Outcome Assessment Life- long after stroke 
in young adults initiative will be the largest study on 
young patients with stroke ever, with more than 10 
000 patients already included.
 ► Sufficient statistical power due to large individual 
data set for subanalysis on stroke subtypes, gender, 
ethnicity, climate.
 ► Risk of misclassification and missing data due to the 
use of existing data gathered with varying protocols 
and cohorts.
 ► Variability in diagnostic workup and non- obligatory 
imaging- based confirmation of stroke due to long 
inclusion period and varying cohorts.
 ► Mainly hospital- based cohorts are included, risking 
inclusion bias.
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worldwide differences in risk factors, causes and outcome of young stroke 
patients.
BACkgRound
Worldwide, 2 million patients aged 18–50 years suffer 
a stroke each year.1 2 Due to physical, cognitive and 
emotional post- stroke consequences faced by individual 
patients after stroke that often occur early in life, our 
societies face high socioeconomic costs.1–3 The absolute 
number of young patients who live with the consequences 
of stroke is expected to increase rapidly due to a rising 
incidence in ischaemic stroke and increasing long- term 
survival.1 2
Patients with stroke at young age comprise a hetero-
geneous group with many different underlying causes. 
Furthermore, the aetiology remains unknown in one- 
third of all young stroke patients.4 Information regarding 
causative risk factors and aetiology and about long- term 
prognosis including the risk of recurrence or death, the 
potential of recovery and the range of sequelae is scarce 
and mainly based on smaller studies.5 Most previous 
studies of young patients with ischaemic stroke comprised 
less than 1000 patients, with even smaller numbers in aeti-
ologic subgroups. Studies regarding young patients with 
intracerebral haemorrhage are even smaller. In addition, 
only few studies have taken ethnicity, geographical region 
and climate of residence into account.1–3 Finally, the 
optimal secondary prevention strategy for young stroke 
patients is poorly defined as numbers of young patients 
are low in randomised trials on secondary prevention.6 
As a consequence, guidelines on secondary prevention or 
counselling after stroke do not provide specific informa-
tion for individual young patients.
Information regarding specific subgroups of young 
ischaemic stroke patients and larger numbers of young 
intracerebral haemorrhage patients are long awaited and 
can be helpful in treating and counselling individual 
patients. Recent reviews have stressed the importance of 
initiating large collaborative studies in order to develop 
reliable prognostic models based on clinical and demo-
graphic features, diagnostics and genetics and establish 
stroke guidelines specifically for patients at young age.6–8
We therefore launched the ‘Global Outcome Assess-
ment Life- long after stroke in young adults’ (GOAL) 
initiative to collect individual patient data worldwide, 
with the aim of performing an individual patient data 
meta- analysis. The GOAL initiative aims to investigate the 
aetiology, risk factors, functional outcome, risk of recur-
rent vascular events and death after stroke on young age 
with special emphasis on ethnic and regional variation.
METhodS
Study objective
The GOAL initiative aims to collect individual patient 
data from young stroke cohorts that included consecutive 
patients. We aim to perform an individual patient data 
meta- analysis to assess aetiology, risk factors, functional 
outcome and prognosis in patients aged 18 up to and 
including 50 (18–50) years with an ischaemic stroke or 
intracerebral haemorrhage (ICH).
Specific study questions
1. What are the risk factors for stroke at young age?
2. What are the causes of stroke in young patients aged 
18–50 years?
3. What is the functional outcome after stroke in patients 
aged 18–50 years?
4. What is the cumulative risk of recurrent vascular events 
and of death in young stroke patients?
5. What are the differences in risk factors and causes of 
stroke, case fatality and prognosis between patients 
with different clinical (eg, stroke subtype) and de-
mographic characteristics (eg, age, sex, ethnicity and 
climate)?
Patient eligibility
Inclusion criteria
1. Ischaemic stroke or intracerebral haemorrhage, ac-
cording to the definition of the WHO.9
2. Age 18–50 years.
3. Available individual patient data including at least one 
of the following variables of interest: risk factors of 
stroke, cause of stroke, functional outcome or follow- 
up data regarding recurrent events and death.
Exclusion criteria
1. Traumatic intracerebral haematoma.
2. Intracerebral haemorrhage or ischaemic stroke due to 
intracerebral malignancy.
3. Subarachnoid haemorrhage.
4. Cerebral venous thrombosis with or without brain isch-
aemia/cerebral haemorrhage.
5. Any iatrogenic stroke as a result of surgery or any other 
medical interventions.
6. Retinal infarction.
definition of stroke
Stroke is defined as a rapidly evolving focal neurological 
deficit, without positive phenomena such as twitches, 
jerks or myoclonus, with no other cause, and symptoms 
persisting for more than 24 hours.9 Stroke will be further 
divided into intracerebral haemorrhage and ischaemic 
stroke based on neuroimaging. Haemorrhagic transfor-
mation of an ischaemic stroke will be classified as an isch-
aemic stroke.
Study design
The GOAL initiative is an international multicenter 
consortium in which individual patient data will be 
collected from young stroke cohorts. The relevant cohort 
studies were identified through a systematic search of 
PubMed using the following Mesh Major Topics: ‘Young 
Adult’, ‘Stroke’, ‘Risk Factors’, ‘Stroke/etiology’, ‘Prog-
nosis’ and ‘Secondary Prevention’ (online supplemen-
tary appendix 1). References of relevant studies were 
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examined to detect other potential cohorts of interest. 
Prospective and retrospective, as well as hospital- based 
and population- based cohorts were considered eligible 
for enrolment if the patients would meet our inclusion 
criteria. The principal investigators were contacted and 
informed about the study with the request to participate. 
Furthermore, when participants indicated they knew of 
other cohorts or collaborators who might be interested 
in participating, we contacted these centres. A specific 
website for potential participants was developed to 
provide more information about the aims of the project 
( www. goalinitiative. org). An overview of the partici-
pating centres is listed in table 1 and figure 1. Analyses 
and results on baseline variables will be conducted and 
before March 2020. Furthermore, the GOAL study strives 
to be as inclusive as possible. Therefore, we have set an 
ongoing open invitation for all researchers in the field 
who are interested in participating. We do this with the 
aim of setting up a worldwide young stroke consortium 
with an ongoing data collection and data analyses on a 
broad range of aspects of young stroke. Therefore, we 
cannot indicate a precise time period for conducting all 
GOAL- related studies.
data collection and storage
Participating centres will be requested to transfer 
their anonymised coded data electronically, according 
to current laws and legislation concerning research 
conduct at each participating research centre, to the 
GOAL- research team of the department of Neurology, 
Radboudumc, Nijmegen. Co- authors who met the ICMJE 
criteria are listed as authors. Other contributors can be 
found in online supplementary appendix 2. Each partici-
pating centre will provide their data by using an encrypted 
excel sheet containing pre- specified variables of interest. 
The key linking anonymised data to individual patients 
will remain at the participating centres. All received 
data will be entered in a uniform database in IBM SPSS 
Statistics V.22 and stored on secured servers at the co- or-
dinating study centre, and will only be accessible to desig-
nated researchers working under the supervision of the 
study co- ordinator. All data will be processed, stored and 
destroyed after end of the study according to European 
Union General Data Protection Regulation.
The data will be verified, before entering the data in 
the uniform database, on data completeness and missing 
data. In case of missing data or inconsistencies with 
published articles, the GOAL research team will contact 
the study investigators to resolve these issues. Data will be 
stored for at least 15 years.
Patient and public involvement
Still, information about the aetiology and prognosis is 
uncertain for many young stroke patients. For both young 
stroke patients and many clinicians treating this patient 
group, the study questions as described earlier are very 
relevant and have high priority.
No patients were involved in the design, recruitment or 
conduction of the study. Study results will be published in 
peer- reviewed journals and be communicated to country- 
specific young stroke communities by participating 
authors.
Sample size and power calculation
Based on our literature search and consequently esti-
mated available patient data, we aim to include at least 
10 000 patients, as this size will allow assessing causes of, 
risk factors for and prognosis of stroke at young age in 
meaningful subgroups.
Baseline variables
Data for each individual patient is collected from the 
hospital at index stroke. Baseline data will include demo-
graphic characteristics, medical history including medi-
cation used on admission and data of diagnostic workup 
within 1 month after the index stroke (table 2).
In addition, the season of the index event and climate 
of the country or region of origin will be registered. The 
climate will be classified according to the Köppen- Geiger 
climate classification system,10 and the season of index 
stroke according to the date of admission (table 3).
The severity of stroke is assessed with the National Insti-
tutes of Health Stroke Scale (NIHSS) score,11 and the 
functional performance with modified Ranking Scale 
(mRS)12 right after a stroke. The mRS will also be assessed 
during follow- up, preferably at 3 months and when avail-
able later during follow- up.
Secondary prevention at admission is categorised as 
antihypertensive medication, HMG- CoA (β-Hydroxy 
β-methylglutaryl- CoA) reductase inhibitors (statins) or 
other cholesterol- lowering medication, platelet aggre-
gation inhibitors (antiplatelets), oral anticoagulants 
(vitamin K antagonists or direct oral anticoagulants).
Death will be analysed based on occurrence within 30 
days (case fatality) or thereafter.
outcomes at baseline
Outcomes will include: cause of stroke, both individu-
ally assessed and according to the trial of ORGg 10172 
in Acute Stroke Treatment (TOAST) criteria13 for isch-
aemic stroke and SMASH- U14 for ICH, stratified for age, 
sex, ethnicity and climate. Other outcomes will include 
frequency and distribution of vascular risk factors, stroke 
severity at baseline by using the NIHSS, functional neuro-
logical outcome at baseline by using the mRS, case fatality 
and the use of secondary prevention at baseline. Consid-
ering that not all patients have had an imaging- confirmed 
stroke, subgroup analyses will be done in patients with 
and without imaging- confirmed stroke when analysing 
the above- mentioned outcomes.
 Risk factors
Cardiovascular risk factors include conventional risk 
factors, as described according to the 2014 guidelines of 
the American Stroke Association15: hypertension, diabetes, 
atrial fibrillation (AF), dyslipidaemia and cigarette 
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Figure 1 Map with participating countries (April 2019).
smoking. Additionally, we will include the following other 
vascular risk factors and diseases: a history of cardiovas-
cular diseases, patent foramen ovale, heavy drinking, 
illicit recent drug use, obesity, hormone replacement 
therapy and recent or acute infection. Previous cardiovas-
cular diseases will include prior stroke or transientisch-
aemic attack (TIA), ischaemic heart disease, heart failure 
and peripheral artery disease (PAD). Table 2 summarises 
the collected vascular risk factors and their definitions/
operationalisation.
 Causes
Ischaemic stroke: Causes of stroke are defined according 
to the TOAST classification.13 Causes of stroke defined 
according to Causative Classification System of ischaemic 
stroke16 and ASCO classification17 will, when available, 
also be collected. The participating centres will also be 
requested to state, if known, the precise cause of the 
stroke (eg, dissection, vasculitis, haematological disorder, 
cardiac condition).
Intracerebral haemorrhage: Location of ICH (lobar/deep, 
supratentorial/infratentorial) will be collected. Also the 
ICH volume, calculated by using the ABC/2 method 
from the axial CT images,18 will be collected. The cause 
of intracerebral haemorrhage will be preferably defined 
according to the SMASH- U14. Aetiology as defined by 
the H- ATOMIC classification will, when available, also be 
collected.14 The precise cause of ICH (as possibly identi-
fied with neuroimaging of the intracranial vasculature) 
will also be requested.
outcome during follow-up
Follow- up evaluation of use of secondary prevention, 
recurrence of vascular events and death has been 
collected differently across the various studies: either in 
person, by telephone interviews with patients or rela-
tives, by collecting hospital/general practitioner medical 
records or discharge diagnosis ICD codes.
The following cardiovascular risk factors will be 
collected at follow- up, whenever available, according to 
the same definitions described at baseline and in table 2: 
hypertension, diabetes mellitus, dyslipidaemia, cigarette 
smoking, obesity, AF, heavy drinking and illicit drug use.
Functional performance will be assessed with the mRS 
score and data on the use of secondary prevention medi-
cation will be collected from the medical records files.
Outcomes will include recurrent vascular events and 
all- cause death. Recurrent vascular events are defined as 
occurrence of any of the following events: TIA (defined 
as in table 2), ischaemic stroke and ICH (defined simi-
larly as baseline events) and other vascular ischaemic 
events, when available. Other vascular ischaemic events 
of interest include angina pectoris, myocardial infarction 
(defined by symptoms of cardiac ischaemia with elec-
trocardiographic changes corresponding to myocardial 
necrosis with or without cardiac biomarker elevation 
or pathological evidence of infarction according to the 
universal definition of myocardial infarction,19 periph-
eral artery disease including revascularisation proce-
dures (coronary artery bypass grafting, percutaneous 
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Table 2 Definitions of baseline demographics and risk factors
Variable or risk factor Definition
Sex Male/female
Age 18–50 years
Ethnicity  ►  Caucasian
 ►  Black
 ►  Hispanic
 ►  Asian
 ►  Aboriginal
 ►  Maori
 ►  Pacific Islander
 ►  Other
Prior stroke or TIA Stroke prior to the index stroke is defined according to the same criteria as the index stroke; a rapidly 
evolving focal neurological deficit, without positive phenomena such as twitches, jerks or myoclonus, 
with no other than vascular cause, with symptoms persisting for more than 24 hours.9 Stroke will 
be further divided into intracerebral haemorrhage and ischaemic stroke based on neuroimaging. 
Haemorrhagic transformation of an ischaemic stroke will be classified as an ischaemic stroke. TIA is 
defined as a history of an episode of focal cerebral dysfunction lasting <24 hours without evidence of 
corresponding ischaemic lesion in earlier or present imaging studies.
Hypertension A history of hypertension was defined as its presence either in the patients’ medical history, or when 
identified during admission for the index event after the acute phase within the first month after stroke. 
Hypertension was defined as the use of antihypertensive medication and/or systolic blood pressure of 
140 mm Hg or greater and/or diastolic blood pressure of 90 mm Hg or greater.
DM A history of DM was defined as its presence either in the patients’ medical history, or when identified 
during admission for the index event. Diabetes was defined as the use of diabetic medication and/or 
a fasting (defined as no caloric intake for at least 8 hours) plasma glucose >7 mmol/L and/or 2 h PG 
≥11.1 mmol/L during OGTT and/or HbA1C≥6.5% (48 mmol/mol) and/or symptoms of hyperglycaemia 
or hyperglycaemic crisis and a random glucose >11.1 mmol/L.20
Dyslipidaemia A history of dyslipidaemia was defined as its presence either in the patients’ medical history, or when 
identified during admission for the index event. Dyslipidaemia was defined as use of statins and/or 
cholesterol level ≥5.0 mmol/L (193 mg/dL) and/or low- density lipoprotein level ≥3.0 mmol/L (116 mg/
dL) and/or high- density lipoprotein level <1.0 mmol/L (39 mg/dL) and/or triglyceride level ≥1.7 mmol/L 
(150 mg/dL).
AF A history of AF (chronic/paroxysmal) was defined as its presence either in the patients’ medical 
history, or when identified during admission for the index event. Atrial fibrillation will be defined as 
diagnosis based on ECG findings.
PFO A presence of PFO was defined based on documentation in medical records, or when identified 
during hospitalisation for the index event. PFO will be defined as PFO with or without atrial septum 
aneurysm, as identified on TTE or TEE with or without contrast.
CAD CAD included myocardial infarction and/or angina pectoris. A history of myocardial infarction or 
angina pectoris was defined as its presence either in the patients’ medical history, or when identified 
during admission for the index event.
Heart failure A history of heart failure was defined as its presence either in the patients’ medical history, or when 
identified during admission for the index event. Heart failure was defined as ejection fraction <55%, 
reported on echocardiogram.
PAD A history of PAD was defined as its presence either in the patients’ medical history, or when identified 
during admission for the index event.
Obesity Obesity was defined as a body mass index greater than 30 kg/m2, measured during admission for the 
index event or when reported by the patient.
Migraine A history of migraine was defined as its presence either in the patients’ medical history or when 
identified during hospitalisation for the index event. Migraine was defined according to the 
International Headache Society criteria.21
Hormone replacement 
therapy
Use of oral or non- oral hormone replacement therapy at admission for the index event.
Oral contraceptives Use of oral contraceptive pills at time of stroke onset.
Continued
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Variable or risk factor Definition
Recent or acute 
infection
Signs or laboratory findings indicative of infection at admission or reported symptoms of any 
infectious disease during the month prior to stroke, or as concluded by institution of cohort.
Ever smoking Any current or former smoker.
Heavy drinking Heavy drinking was defined as the consumption of more than 21 units a week for men and 14 units a 
week for women, identified at admission for the index event.
Illicit recent drug use Within the month prior to stroke.
Family history of stroke History of ischaemic/haemorrhagic stroke or TIA in a first- degree relative.
Index stroke related to 
pregnancy
 ►  No
 ►  Yes, pregnant at time of stroke
 ►  Yes, stroke <6 weeks postpartum
 ►  Yes, stroke <1 year after pregnancy
Pregnancy- related 
complications during 
any pregnancy
 ►  Gestational diabetes
 ►  Hypertension
 ►  Pre- eclampsia
 ►  HELLP syndrome
AF, atrial fibrillation; CAD, coronary artery disease; DM, diabetes mellitus; HbA1c, glycosylated haemoglobin, type A1c; OGTT, oral glucose 
tolerance test;PAD, peripheral artery disease ; PFO, patent foramen ovale;2 h PG, 2 hours post glucose; HELLP syndrome, haemolysis 
elevated liver enzymes and low platelets syndrome; TEE, transoesophageal echocardiogram;TIA, transient ischaemic attack ; TTE, 
transthoracic echocardiogram.
Table 2 Continued
transluminal coronary angioplasty, carotid endarterec-
tomy or other peripheral arterial revascularisation proce-
dures). All outcomes had to be confirmed by physicians 
from the appropriate specialty through medical records, 
or through the appropriate ICD code.
Statistical analysis
We aim to perform statistical analyses with IBM SPSS 
Statistics or R (most recent versions). A p value of<0.05 
with correction for multiple testing when appropriate 
will be considered statistically significant, and/or a 95% 
CI not containing 1. Subanalysis to identify differences 
in demographic characteristics including gender, age, 
ethnicity, pregnancy- related stroke, climate and season at 
time of admission will be performed.
Differences between groups will be compared using 
ANOVA test, Student’s t- test for continuous variables and 
χ2 test for categorical variables. Univariate multivariable 
logistic regression analysis will be performed to deter-
mine risk factors and potential trigger factors. In case 
of missing data at baseline, and if considered necessary, 
multiple imputation will be used. The cumulative risk of 
death and vascular events will be calculated with Kaplan–
Meier survival analysis. Differences in survival between 
different subgroups will be assessed using Log- Rank tests. 
In the analysis for vascular events, patients who have died 
or were lost to follow- up will be censored from the last 
available follow- up. We will use Cox regression models to 
obtain HRs and their corresponding 95% CIs to calculate 
the risk of death and recurrent vascular events between 
different aetiologies and demographic characteristics 
while adjusting for confounders. Only patients for whom 
follow- up data is available will be included for these sepa-
rate analyses.
dISCuSSIon
The GOAL initiative aims to investigate the causes and 
risk factors of ischaemic stroke and ICH in young patients, 
aged 18 to 50 years, to determine functional outcome, 
and the risk of new or recurrence of vascular events, and 
to study variation according to aetiological subgroups, 
geographical region, continent and ethnicity. The most 
important strength of our study is the participation of 
to date 30 stroke centres throughout the world, from 29 
different countries across all continents (figure 1). By 
combining existing individual data sets, the GOAL initia-
tive will be the largest study on young patients with stroke 
ever, with more than 10 000 patients already included. 
This large set of individual patient data provides suffi-
cient statistical power to not only reliably quantify the 
differences in risk factors and aetiology of stroke between 
men and women, different age groups, ethnic subgroups 
and possibly search for differences between climates of 
residence, but also assess the risk of recurrent vascular 
events.
The study has also its limitations. There will be a risk 
of misclassification of aetiology, risk factors and events of 
interest during follow- up, as we will make use of already 
existing data that have been collected according to 
various local protocols that will not be completely iden-
tical. We will harmonise variables across studies as much 
as possible. There may also be a risk of missing data, as 
we have included studies that were designed prior to 
the GOAL initiative, and therefore did not include all 
variables of interest. Furthermore, our study will cover 
a long time period in which data collection took place. 
This may lead to variability in the diagnostic workup and 
differences in brain imaging protocols due to adjusted 
copyright.
 o
n
 N
ovem
ber 29, 2019 at E-Library Insel. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-031144 on 14 November 2019. Downloaded from 
9Ekker M, et al. BMJ Open 2019;9:e031144. doi:10.1136/bmjopen-2019-031144
Open access
Table 3 Classification of climates and seasons
Climate of country of 
origin/city of study 
hospital
Köppen- Geiger climate 
classification system
A (Tropical)
 ► f (rainforest)
 ► m (monsoon)
 ► w (savanna)
B (Arid)
 ► W (desert)
 ► S (steppe)
 – h (hot)
 – k (cold)
C (Temperate)
 ► s (dry summer)
 ► w (dry winter)
 ► f (without dry season)
 – a (hot summer
 – b (warm summer)
 – c (cold summer)
D (Continental)
 ► s (dry summer)
 ► w (dry winter)
 ► f (without dry season)
 – a (hot summer
 – b (warm summer)
 – c (cold summer)
E (Polar)
 ► T (tundra)
 ► F (frost)
Season of index 
stroke
Northern hemisphere countries 
(Austria, Belgium, Canada, Estonia, 
Finland, France, Germany, Ghana, 
India, Israel, Italy, Japan, Mexico, 
Mongolia, The Netherlands, Nigeria, 
Norway, Portugal, Republic of Korea, 
Sweden, Switzerland, Taiwan, Turkey, 
UK, USA, UnitedArab Emirates) :
 ► Spring: March–May
 ► Summer: June–August
 ► Fall: September–November
 ► Winter: December–February
Southern hemisphere countries 
(Australia, Brazil, Costa Rica, New 
Zealand, South Africa):
 ► Spring: September–November
 ► Summer: December–February
 ► Fall: March–May
 ► Winter: June–August
 ► Equatorial countries: Malaysia
guidelines and improvements in imaging techniques. For 
instance, not all patients will have undergone complete 
cardiac examination (eg, both transthoracic and tran-
soesophageal echocardiography, prolonged ECG), which 
may lead to an underestimation of the frequency of 
cardio- embolic strokes. Moreover, included cohorts are 
mainly hospital- based. In addition, not all cohorts will 
have had the same inclusion criteria, which may lead to 
an underestimation of case fatality. Finally, imaging- based 
confirmation of the stroke was neither mandatory nor 
available in all cohorts, although very few patients were 
diagnosed with stroke based on clinical symptoms alone, 
and all patients included were identified and treated as 
strokes by their main physicians.
In conclusion, the GOAL initiative will include data of 
at least 10 000 patients with a stroke at young age from 
six continents, providing sufficient patient numbers to 
allow for individual patient data meta- analysis. The size of 
this study will allow for detailed description of the global 
distribution of causes and risk factors, and for the quanti-
fication of the cumulative risk of outcomes.
The GOAL initiative explicitly reaches out to other 
researchers and aims to become a platform that facili-
tates future collaborative research in the area of stroke at 
young age. We envision enriching the cohort with genetic 
and imaging data and long- term outcomes.
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